| Autor: |
Østergaard, M., Baslund, B., Rigby, W., Rojkovich, B., Jorgensen, C., Dawes, P. T., Wiell, C., Wallace, D. J., Tamer, S. C., Kastberg, H., Petersen, J., Sierakowski, S. |
| Předmět: |
|
| Zdroj: |
Arthritis & Rheumatism; Jan2011, Vol. 63 Issue 1, p305-305, 1p |
| Abstrakt: |
A response by M. Østergaard and colleagues to a letter to the editor about their article "Ofatumumab, a human anti-CD20 monoclonal antibody, for treatment of rheumatoid arthritis with an inadequate response to one or more diseasemodifying antirheumatic drugs: results of a randomized, double-blind, placebo-controlled, phase I/II study" in the August 2010 issue is presented. |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text